These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28927716)

  • 41. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Powdered red yeast rice and plant stanols and sterols to lower cholesterol.
    Feuerstein JS; Bjerke WS
    J Diet Suppl; 2012 Jun; 9(2):110-5. PubMed ID: 22531006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.
    Saunders E; Ferdinand K; Yellen LG; Tonkon MJ; Krug-Gourley S; Poland M
    J Natl Med Assoc; 2000 Jul; 92(7):319-26. PubMed ID: 10946527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Acta Cardiol; 2006 Jun; 61(3):263-9. PubMed ID: 16869445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
    Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
    Folse HJ; Goswami D; Rengarajan B; Budoff M; Kahn R
    Atherosclerosis; 2014 Sep; 236(1):154-61. PubMed ID: 25050538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia.
    Vladimirova-Kitova LG; Deneva TI; Marinov B
    Cardiovasc Ther; 2011 Oct; 29(5):340-8. PubMed ID: 20345493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy.
    Zhao W; Zheng XL; Jiang ZN; Liao XB; Zhao SP
    Int J Cardiol; 2017 Dec; 248():355-360. PubMed ID: 28689987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of patients with statin intolerance.
    Fischer S; Julius U
    Atheroscler Suppl; 2017 Nov; 30():33-37. PubMed ID: 29096858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
    Maddox TM; Borden WB; Tang F; Virani SS; Oetgen WJ; Mullen JB; Chan PS; Casale PN; Douglas PS; Masoudi FA; Farmer SA; Rumsfeld JS
    J Am Coll Cardiol; 2014 Dec; 64(21):2183-92. PubMed ID: 25447259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [We prefer to call it "statin therapy."].
    Schmidt H
    MMW Fortschr Med; 2014 Oct; 156(17):17. PubMed ID: 25417456
    [No Abstract]   [Full Text] [Related]  

  • 59. How do we improve patient compliance and adherence to long-term statin therapy?
    Maningat P; Gordon BR; Breslow JL
    Curr Atheroscler Rep; 2013 Jan; 15(1):291. PubMed ID: 23225173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular prevention: lifestyle and statins--competitors or companions?
    Opie LH; Dalby AJ
    S Afr Med J; 2014 Mar; 104(3):168-73. PubMed ID: 24897816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.